权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Johns Hopkins Institute for Clinical and Translational Research

约翰·霍普金斯临床与转化研究所

基本信息

批准号：
10398028
负责人：
Daniel Ernest Ford
金额：
$ 944.74万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-05-31 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10398028
关键词：
Accident and Emergency department Address Alzheimer&apos s Disease American Baltimore Budgets Clinic Clinical Research Collaborations Communication Communities Complex Conduct Clinical Trials Consultations Country Data Databases Diagnosis Disease Ecosystem Engineering Environment Funding Goals Health Health Promotion Health Status Health system Healthcare Healthcare Systems Home Hospitalization Hospitals Incentives Individual Informatics Information Systems Institutes Institution Insurance Interdisciplinary Study Intervention Joints Laboratories Lead Leadership Learning Maryland Measurable Medicare Mentors Methodology Mission Modeling Multiple Partners Obesity Outcome Pathway interactions Patients Pharmacy Schools Phase Population Population Group Population Heterogeneity Prevention Public Health Randomized Clinical Trials Research Research Personnel Research Support Research Training Resources Safety Science Scientist Services Sexually Transmitted Diseases Specialist Speed Substance abuse problem Technology Training Training Programs Translating Translational Research Translations Universities Vision Work care outcomes clinical infrastructure drug development drug discovery effective therapy experience global health health care availability health care delivery health disparity improved individual patient innovation investigator training multidisciplinary next generation novel therapeutics patient population population health precision medicine programs skills translational scientist waiver

项目摘要

Contact PD/PI: Ford, Daniel Ernest The Johns Hopkins Institute for Clinical and Translational Research (ICTR) has been a productive, innovative and impactful organization in transforming how clinical and translational research is conducted throughout Johns Hopkins University. Enhancing collaborative research teams, advancing informatics, promoting new methodologies, providing access to regulatory support, and bringing researchers and the community closer together as true partners in discovery have all made translational research more successful. Over the next five years, the Johns Hopkins ICTR will move beyond its current research community to create a comprehensive regional hub that includes new partners – the University of Maryland Baltimore (UMB), Morgan State University (MSU) and Kaiser Permanente Mid-Atlantic States (KPMAS). These partners bring complementary expertise and connections to distinct populations. Together, we have an opportunity to conduct high quality innovative research, and rapidly implement findings that impact the health of our state and region. Building on our extensive connections with community groups, we will move to a new phase of joint governance with bidirectional communication and participation on key ICTR committees. New programs will include a Trial Innovation Unit that will focus on improving methodologic and operational support for research teams conducting randomized clinical trials so that the impact of these trials is enhanced. A goal of this Unit will be to pilot and disseminate approaches that move randomized clinical trials closer to the precision medicine paradigm, with a focus on outcomes of greatest value to individual patients. Combining drug discovery scientists at Johns Hopkins with experts at the UMB School of Pharmacy, the ICTR will create a new Drug Discovery and Development Core. KPMAS and Johns Hopkins will continue to jointly fund programs that push the boundaries of how a Learning Health Care system can improve health outcomes. The ICTR provides a model for training investigators to work in multidisciplinary teams with experienced mentors using the most rigorous methodologies. We will enhance our training programs by incorporating principles of biodesign from the engineering tradition into the experience of all trainees. This places a higher emphasis on identification of the problem, engaging important stakeholders (clinicians, patients, IT professionals) to develop solutions, and identifying the most effective pathways to dissemination. Translational research demands the skills of many professionals working together to address complex problems. The Johns Hopkins ICTR is poised to leverage our current services to benefit new partners who have extensive responsibility for the conduct of research and health care delivery in Maryland. Working together, we expect to have a measurable impact on translational research in Maryland. Page 679 Project Summary/Abstract Contact PD/PI: Ford, Daniel Ernest By identifying and overcoming barriers in the translational pathway, increasing scientific collaboration, providing consultative services, clinical infrastructure, and technology cores that bridge the gap between the laboratory and the clinic, the ICTR helps to speed the pace of scientific discovery, bringing effective therapies to the public, and ultimately improving the health of Americans. Page 680

联系PD/PI：福特，丹尼尔·欧内斯特